Balance Sheet

Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Vanda Pharmaceuticals (VNDA) Change in Intangibles (2018)

Vanda Pharmaceuticals' Change in Intangibles history spans 2 years, with the latest figure at $25.0 million for Q3 2018.

On a quarterly basis, Change in Intangibles changed N/A to $25.0 million in Q3 2018 year-over-year; TTM through Dec 2019 was $25.0 million, a 50.0% decrease, with the full-year FY2018 number at $25.0 million, changed N/A from a year prior.
Change in Intangibles hit $25.0 million in Q3 2018 for Vanda Pharmaceuticals, roughly flat from $25.0 million in the prior quarter.
Over the last five years, Change in Intangibles for VNDA hit a ceiling of $25.0 million in Q2 2018 and a floor of $8.0 million in Q1 2014.